With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
ApexOnco Front Page
Recent articles
The company’s AN9025 will shortly enter phase 1.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Interius, one of the most advanced players, will cost $350m.
Posters and mini-orals include another VEGF bispecific.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Summit and Nuvalent have scored prized plenary spots.
